According to TipRanks.com, Newitter is a 5-star analyst with an average return of 24.2% and a 66.9% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Treace Medical Concepts, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intersect ENT with a $27.33 average price target, which is a 26.8% upside from current levels. In a report issued on July 22, BTIG also maintained a Buy rating on the stock with a $32.00 price target.
Based on Intersect ENT’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $24.33 million and GAAP net loss of $20.03 million. In comparison, last year the company earned revenue of $19.83 million and had a GAAP net loss of $17.53 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.
Read More on XENT:
- Leerink Partners Keeps a Buy Rating on Landos Biopharma (LABP)
- Leerink Partners Thinks Teladoc’s Stock is Going to Recover
- Mirum Pharmaceuticals (MIRM) Gets a Buy Rating from Leerink Partners
- Analysts Conflicted on These Technology Names: Intel (INTC) and Twitter (TWTR)
- Analysts Offer Insights on Materials Companies: and Celanese (CE)